Non-Executive Director (representing Touchstone Innovations)
Bobby’s career in the life sciences industry spans 17 years. He joined Touchstone Innovations as Director of Healthcare Investments in September 2015. Prior to Touchstone Innovations, Bobby was Investment Director of Novo Seeds, the early stage investment arm of Novo AS. He led investments there in several seed stage companies including Acesion, Avilex, RSPR Pharma, and Contera Pharma (exited). His experience also includes drug development (Maxygen), business development (LEO pharma) and venture capital investing. Bobby obtained his PhD in Biology from University of Virginia (working from Imperial College London), and his BS in Biochemistry at the University of Rochester.